Luke Sergott
Stock Analyst at Barclays
(2.31)
# 2,584
Out of 5,172 analysts
389
Total ratings
39.45%
Success rate
-1.2%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Maintains: Equal-Weight | $200 → $120 | $99.70 | +20.36% | 24 | Mar 9, 2026 | |
| MEDP Medpace Holdings | Upgrades: Equal-Weight | $500 | $452.51 | +10.49% | 7 | Mar 6, 2026 | |
| PACB Pacific Biosciences of California | Downgrades: Underweight | $2 → $1.5 | $1.33 | +12.78% | 7 | Mar 6, 2026 | |
| IQV IQVIA Holdings | Upgrades: Overweight | $210 | $166.07 | +26.45% | 26 | Mar 6, 2026 | |
| CERT Certara | Downgrades: Equal-Weight | $8 | $6.15 | +30.08% | 22 | Mar 6, 2026 | |
| AVTR Avantor | Downgrades: Underweight | $8.5 | $7.51 | +13.18% | 29 | Mar 6, 2026 | |
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $15 → $12 | $9.53 | +25.92% | 15 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $150 | $111.30 | +34.77% | 15 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $200 → $175 | $113.88 | +53.67% | 5 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $215 → $200 | $153.60 | +30.21% | 12 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $265 | $237.03 | +11.80% | 5 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $33.35 | +49.93% | 9 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $400 | $298.99 | +33.78% | 19 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $50 | $42.07 | +18.85% | 21 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $118 | $85.94 | +37.31% | 13 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $625 → $650 | $474.39 | +37.02% | 30 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $52 | $39.93 | +31.18% | 3 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $270 | $195.28 | +38.26% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,600 → $1,550 | $1,204.48 | +28.69% | 4 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $110 | $124.33 | -11.53% | 22 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $120 | $85.18 | +40.88% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $22 | $18.39 | +19.63% | 15 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 → $105 | $104.91 | +0.09% | 9 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $13.50 | +48.15% | 23 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $250 | $189.35 | +32.03% | 41 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $90.78 | -0.86% | 1 | Aug 1, 2025 |
ICON Public Limited Company
Mar 9, 2026
Maintains: Equal-Weight
Price Target: $200 → $120
Current: $99.70
Upside: +20.36%
Medpace Holdings
Mar 6, 2026
Upgrades: Equal-Weight
Price Target: $500
Current: $452.51
Upside: +10.49%
Pacific Biosciences of California
Mar 6, 2026
Downgrades: Underweight
Price Target: $2 → $1.5
Current: $1.33
Upside: +12.78%
IQVIA Holdings
Mar 6, 2026
Upgrades: Overweight
Price Target: $210
Current: $166.07
Upside: +26.45%
Certara
Mar 6, 2026
Downgrades: Equal-Weight
Price Target: $8
Current: $6.15
Upside: +30.08%
Avantor
Mar 6, 2026
Downgrades: Underweight
Price Target: $8.5
Current: $7.51
Upside: +13.18%
Fortrea Holdings
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $9.53
Upside: +25.92%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $165 → $150
Current: $111.30
Upside: +34.77%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $200 → $175
Current: $113.88
Upside: +53.67%
Charles River Laboratories International
Feb 19, 2026
Maintains: Overweight
Price Target: $215 → $200
Current: $153.60
Upside: +30.21%
Feb 13, 2026
Maintains: Equal-Weight
Price Target: $325 → $265
Current: $237.03
Upside: +11.80%
Feb 13, 2026
Maintains: Overweight
Price Target: $55 → $50
Current: $33.35
Upside: +49.93%
Feb 11, 2026
Reinstates: Overweight
Price Target: $400
Current: $298.99
Upside: +33.78%
Feb 3, 2026
Maintains: Overweight
Price Target: $39 → $50
Current: $42.07
Upside: +18.85%
Feb 3, 2026
Maintains: Overweight
Price Target: $115 → $118
Current: $85.94
Upside: +37.31%
Jan 30, 2026
Maintains: Overweight
Price Target: $625 → $650
Current: $474.39
Upside: +37.02%
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $39.93
Upside: +31.18%
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $195.28
Upside: +38.26%
Dec 15, 2025
Maintains: Overweight
Price Target: $1,600 → $1,550
Current: $1,204.48
Upside: +28.69%
Dec 15, 2025
Maintains: Underweight
Price Target: $100 → $110
Current: $124.33
Upside: -11.53%
Dec 15, 2025
Maintains: Overweight
Price Target: $85 → $120
Current: $85.18
Upside: +40.88%
Dec 15, 2025
Maintains: Overweight
Price Target: $17 → $22
Current: $18.39
Upside: +19.63%
Nov 21, 2025
Downgrades: Equal-Weight
Price Target: $77 → $105
Current: $104.91
Upside: +0.09%
Nov 5, 2025
Maintains: Overweight
Price Target: $19 → $20
Current: $13.50
Upside: +48.15%
Oct 22, 2025
Maintains: Overweight
Price Target: $225 → $250
Current: $189.35
Upside: +32.03%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $90.78
Upside: -0.86%